ClinicalTrialsFinder
RecruitingPhase 3NCT06363370

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Human Interferon α1b Inhaled Solution in the Treatment of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Children.

Sponsor

Kexing Biopharm Co., Ltd.

Enrollment

322 participants

Start Date

Mar 27, 2024

Study Type

INTERVENTIONAL

Conditions

Respiratory Syncytial Virus Infections

Summary

To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection.

Eligibility

Min Age: 2 MonthsMax Age: 2 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Human interferon α1b Inhalation Solution and a drug called Inhalation Solution Placebo for people with respiratory syncytial virus infections. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Months to 2 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHuman interferon α1b Inhalation Solution

Participants will receive Human interferon α1b Inhalation Solution

DRUGInhalation Solution Placebo

Participants will receive Inhalation Solution Placebo

Locations(1)

Children's Hospital, Capital Institute of Pediatrics

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06363370

Related Trials

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

NCT0721457180 locations

A Study of BLB-201 RSV Vaccine in Infants and Children

NCT0565518215 locations

A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.

NCT076585349 locations

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

NCT066843793 locations

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

NCT0722010915 locations